M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post...
HCPCS Procedure & Supply Codes
M0241 - Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Access to this feature is available in the following products:
Find-A-Code Essentials
Find-A-Code Professional
Find-A-Code Premium
Find-A-Code Elite
Find-A-Code Facility Base
Find-A-Code Facility Plus
Find-A-Code Facility Complete
HCC Standard
HCC Pro
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information.
Additional Code Information (Global Days, MUEs, etc.)
Additional Code Information includes:
APC Status Indicator
Assistant Surgeon (80, 82)
Bilateral Surgery (50)
CCS Clinical Classification
Co-Surgeons (62)
Diagnostic Imaging Family
Facility MUEs
Global Days
Hierarchical Condition Categories (HCC)
Major Complications or Comorbidities (MCC/CC)
Medicare Status Code
Multiple Procedures (51)
Non-Facility MUEs
OTS Orthotic
PC/TC Indicator (26)
Physician Supervisions
Team Surgery (66)
Type Of Service (TOS)
and more...
Access to this feature is available in the following products:
Find-A-Code Professional
Find-A-Code Premium
Find-A-Code Elite
Find-A-Code Facility Base
Find-A-Code Facility Plus
Find-A-Code Facility Complete
HCC Standard
HCC Pro
Top Modifiers - Most Often Billed
Save time with a Professional or Facility subscription! You will be able to see the most common modifiers billed to Medicare along with this code.
Important: This product is not authorized for administration until further notice by the FDA.
Labeler
Vaccine Procedure
Payment Allowance
Effective From
Effective To
Footnotes
My Fee
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
$750.00
2020-07-30
2022-01-24
[3][6][9]
(your fee)
[3] These rates will be geographically adjusted for many providers.
[6] On July 30, 2021, the FDA revised the EUA for casirivimab and imdevimab to allow its use for post-exposure prophylaxis (PEP) in certain adult and pediatric patients. For patients who meet the criteria for repeat dosing, the authorized dosage is an initial dose of 1200 mg, followed by subsequent repeat dosing of 600 mg once every 4 weeks for the duration of ongoing exposure. As a result, CMS issued a new product code for casirivimab and imdevimab of 600 mg (Q0240), and 2 new codes for the administration of repeat doses of casirivimab and imdevimab (M0240/M0241). Providers and suppliers who administer casirivimab and imdevimab for PEP should use M0243 or M0244 for administering the first dose and M0240 or M0241 for administering subsequent repeat doses.
[9] On January 24, 2022, the FDA announced that, due to the high frequency of the Omicron variant, this product isn’t currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.
Quick, Current, Complete - www.findacode.com